title: Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation.
abstract: One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45% ± 9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.
authors.affiliation: Bone Marrow and Stem Cell Transplantation Program, King Hussein Cancer Center, Amman, Jordan.
authors.forename: Ayad Ahmed
authors.initials: AA
authors.lastname: Hussein
authors.affiliation: BMT Centre Leiden, Leiden University Hospital, Leiden, The Netherlands.
authors.forename: Constantijn M
authors.initials: CM
authors.lastname: Halkes
authors.affiliation: Department of Hematology-BMT, Hospital St Louis, Paris, France.
authors.forename: Gérard
authors.initials: G
authors.lastname: Socié
authors.affiliation: Hematology Division, Basel University Hospital, Basel, Switzerland.
authors.forename: André
authors.initials: A
authors.lastname: Tichelli
authors.affiliation: BMT Centre Leiden, Leiden University Hospital, Leiden, The Netherlands.
authors.forename: Peter A
authors.initials: PA
authors.lastname: von dem Borne
authors.affiliation: Department of Hematology and Radboud Institute of Molecular Life Sciences, Radboud University-Nijmegen Medical Centre, Nijmegen, The Netherlands.
authors.forename: Michel N P M
authors.initials: MN
authors.lastname: Schaap
authors.affiliation: Department of Cellular Biotechnology and Hematology, La Sapienza University, Rome, Italy.
authors.forename: Robin
authors.initials: R
authors.lastname: Foa
authors.affiliation: Department of Hematology, Homeostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
authors.forename: Arnold
authors.initials: A
authors.lastname: Ganser
authors.affiliation: Institute G. Gaslini, Genova, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Dufour
authors.affiliation: Department of Haematology II, Ospedale San Martino, Genova, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Bacigalupo
authors.affiliation: Haematology and SCT Unit, Ospedale San Camillo, Rome, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Locasciulli
authors.affiliation: Department of Oncology (Section of Adult Hematology/BMT), King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Aljurf
authors.affiliation: Stem Cell Transplantation Unit, St Anna Kinderspital, Vienna, Austria.
authors.forename: Christina
authors.initials: C
authors.lastname: Peters
authors.affiliation: Department of Hematology-BMT, Hospital St Louis, Paris, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Robin
authors.affiliation: EBMT Data Office, Department of Medical Statistics and Bioinformatics, LUMC, Leiden, The Netherlands.
authors.forename: Anja A
authors.initials: AA
authors.lastname: van Biezen
authors.affiliation: Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
authors.forename: Liisa
authors.initials: L
authors.lastname: Volin
authors.affiliation: Department of Hematology and Radboud Institute of Molecular Life Sciences, Radboud University-Nijmegen Medical Centre, Nijmegen, The Netherlands.
authors.forename: Theo
authors.initials: T
authors.lastname: De Witte
authors.affiliation: Department of Haematological Medicine, GKT School of Medicine, London, United Kingdom.
authors.forename: Judith
authors.initials: J
authors.lastname: Marsh
authors.affiliation: Hematology Division, Basel University Hospital, Basel, Switzerland. Electronic address: jpassweg@uhbs.ch.
authors.forename: Jakob R
authors.initials: JR
authors.lastname: Passweg
authors.affiliation: Bone Marrow Transplantation Center, University Hospital Eppendorf, Hamburg, Germany.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Kröger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005060:Europe; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D007938:Leukemia; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes; D009364:Neoplasm Recurrence, Local; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014184:Transplantation, Homologous / Q000009:adverse effects*; D016896:Treatment Outcome; D055815:Young Adult
keywords: Acute myelogenous leukemia; Hematopoietic stem cell transplantation; Myelodysplastic syndrome; Severe aplastic anemia